|
mutLBSgeneDB |
| |
| |
| |
| |
| |
| |
|
| Gene summary for CD2AP |
 Gene summary |
| Basic gene Info. | Gene symbol | CD2AP |
| Gene name | CD2-associated protein | |
| Synonyms | CMS | |
| Cytomap | UCSC genome browser: 6p12 | |
| Type of gene | protein-coding | |
| RefGenes | NM_012120.2, | |
| Description | Cas ligand with multiple Src homology 3 (SH3) domainsadapter protein CMScas ligand with multiple SH3 domains | |
| Modification date | 20141207 | |
| dbXrefs | MIM : 604241 | |
| HGNC : HGNC | ||
| Ensembl : ENSG00000198087 | ||
| HPRD : 05026 | ||
| Vega : OTTHUMG00000014799 | ||
| Protein | UniProt: Q9Y5K6 go to UniProt's Cross Reference DB Table | |
| Expression | CleanEX: HS_CD2AP | |
| BioGPS: 23607 | ||
| Pathway | NCI Pathway Interaction Database: CD2AP | |
| KEGG: CD2AP | ||
| REACTOME: CD2AP | ||
| Pathway Commons: CD2AP | ||
| Context | iHOP: CD2AP | |
| ligand binding site mutation search in PubMed: CD2AP | ||
| UCL Cancer Institute: CD2AP | ||
| Assigned class in mutLBSgeneDB | C: This gene just belongs to mutLBSgenes. | |
| Gene ontology having evidence of Inferred from Direct Assay (IDA) from Entrez |
| GO ID | GO Term | PubMed ID |
| Top |
| Ligand binding site mutations for CD2AP |
| Lollipop-style diagram of mutations at LBS in amino-acid sequence. We represented ligand binding site mutations only. (You can see big image via clicking.)  : non-synonymous mutation on LBS, Circle size denotes number of samples. |
 |
| Cancer type specific mutLBS sorted by frequency |
| LBS | AAchange of nsSNV | Cancer type | # samples | V141 | E140D | COAD | 1 | E35 | E35G | UCEC | 1 |
| cf) Cancer type abbreviation. BLCA: Bladder urothelial carcinoma, BRCA: Breast invasive carcinoma, CESC: Cervical squamous cell carcinoma and endocervical adenocarcinoma, COAD: Colon adenocarcinoma, GBM: Glioblastoma multiforme, LGG: Brain lower grade glioma, HNSC: Head and neck squamous cell carcinoma, KICH: Kidney chromophobe, KIRC: Kidney renal clear cell carcinoma, KIRP: Kidney renal papillary cell carcinoma, LAML: Acute myeloid leukemia, LUAD: Lung adenocarcinoma, LUSC: Lung squamous cell carcinoma, OV: Ovarian serous cystadenocarcinoma, PAAD: Pancreatic adenocarcinoma, PRAD: Prostate adenocarcinoma, SKCM: Skin cutaneous melanoma, STAD: Stomach adenocarcinoma, THCA: Thyroid carcinoma, UCEC: Uterine corpus endometrial carcinoma. |
| Top |
| Protein structure related information for CD2AP |
| Relative protein structure stability change (ΔΔE) using Mupro 1.1 Mupro score denotes assessment of the effect of mutations on thermodynamic stability. (ΔΔE<0: mutation decreases stability, ΔΔE>0: mutation increases stability) |
 : nsSNV at non-LBS : nsSNV at LBS |
 |
| nsSNVs sorted by the relative stability change of protein structure by each mutation Blue: mutations of positive stability change. and red : the most recurrent mutation for this gene. |
| LBS | AAchange of nsSNV | Relative stability change | V141 | E140D | -1.3510965 | E35 | E35G | -0.916862 |
| (MuPro1.1: Jianlin Cheng et al., Prediction of Protein Stability Changes for Single-Site Mutations Using Support Vector Machines, PROTEINS: Structure, Function, and Bioinformatics. 2006, 62:1125-1132) |
| Structure image for CD2AP from PDB |
| Top |
| Differential gene expression and gene-gene network for CD2AP |
| Differential gene expression between mutated and non-mutated LBS samples in all 16 major cancer types |
| Differential co-expressed gene network based on protein-protein interaction data (CePIN) |
| Top |
| Top |
| Phenotype information for CD2AP |
| Gene level disease information (DisGeNet) |
| Disease ID | Disease name | # PubMed | Association type |
| umls:C0017668 | Glomerulosclerosis, Focal Segmental | 9 | Biomarker, GeneticVariation |
| umls:C0002395 | Alzheimer Disease | 3 | Biomarker, GeneticVariation |
| Mutation level pathogenic information (ClinVar annotation) |
| Allele ID | AA change | Clinical significance | Origin | Phenotype IDs |
| Top |
| Pharmacological information for CD2AP |
| Gene expression profile of anticancer drug treated cell-lines (CCLE) Heatmap showing the correlation between gene expression and drug response across all the cell-lines. We chose the top 20 among 138 drugs.We used Pearson's correlation coefficient. |
 |
| Drug information targeting mutLBSgene (Approved drugs only) |
| Drug status | DrugBank ID | Name | Type | Drug structure |
| Gene-centered ligand-gene interaction network |
 |
| Ligands binding to mutated ligand binding site of CD2AP go to BioLip |
| Ligand ID | Ligand short name | Ligand long name | PDB ID | PDB name | mutLBS | III | Peptide ligand (PRO,PRO,LYS,PRO,ARG,PRO,ARG,ARG) | 2j6f | A | E35 | III | Peptide ligand (PRO,LEU,PRO,ARG,PRO,ARG,VAL) | 2j6o | A | E35 | III | Peptide ligand (GLY,PRO,PRO,LEU,PRO,ARG,PRO,ARG,VAL) | 2j7i | A | E35 | III | Peptide ligand (LYS,GLY,PRO,PRO,LEU,PRO,ARG,PRO,ARG,VAL) | 2j7i | B | E35 | III | Peptide ligand (GLN,PRO,PRO,VAL,PRO,PRO,PRO,ARG,LYS,LYS,ARG,ILE,SER,NH2) | 3u23 | A | V141 |
| Top |
| Conservation information for LBS of CD2AP |
| Multiple alignments for Q9Y5K6 in multiple species |
| LBS | AA sequence | # species | Species |
 |
Copyright © 2016-Present - The University of Texas Health Science Center at Houston |